NAGPUR, India, Oct. 9, 2015 /PRNewswire-iReach/ -- The report
"Gene Therapies: A Diverse Range of Technologies with a
Promising Long-Term Outlook" discusses all gene therapies under
the broad criteria of genetic material introduced to the cell for a
therapeutic purpose. It includes not only the insertion of a gene
into the cell for expression, but also gene silencing with RNA
interference (RNAi) and antisense RNA, aptamers (DNA or RNA
polymers which bind to a protein target), and oncolytic viruses.
Despite few products having so far reached the market and captured
strong revenues, the gene therapies pipeline remains large, with
906 products in active development across all stages. However, the
majority of these remain in early steps of development, with 76% at
either the Discovery or Preclinical stage.
Photo - http://photos.prnewswire.com/prnh/20151009/275690
The company's latest report "Gene Therapies: A Diverse Range
of Technologies with a Promising Long-Term Outlook" states that
oncology, infectious diseases, genetic disorders, cardiovascular
diseases and ophthalmological indications are the most active
pipeline sectors, as well as the most widely studied in terms of
the number of clinical trials. There are 266 pipeline gene
therapies in active development for oncology, more than double that
of central nervous system disorders, which is the second-largest
therapy area. Furthermore, oncology also accounted for 64% of gene
therapies clinical trials between 1989 and 2012.
Make an Inquiry before purchasing this report @
https://wiseguyreports.com/enquiry/gene-therapies-a-diverse-range-of-technologies-with-a-promising-long-term-outlook
. (Single User License - $2995)
Gene therapies have been in development in humans for 25 years,
and a number of products have begun to enter the pharmaceutical
market. However, due to various challenges and clinical trial
setbacks, progress in developing this technology and achieving
suitability for commercial usage has been slow. Gene therapies only
account for a marginal market share and many efficacy and safety
concerns remain unaddressed. However, the pipeline is robust; 906
pipeline gene therapies are currently in development. Most are at
an early stage of development, with 76% at the Discovery or
Preclinical stage. However, there are currently 23 gene therapy
programs in Phase III development and two at the Pre-registration
stage. This indicates that although gene therapies are beginning to
reach the market after two decades of research in humans, the
majority remain in relatively early development.
Scope of this report includes:
Despite 25 years of clinical research, only a few gene therapies
of all types have reached the market globally, and none have
achieved strong clinical or commercial success -
- Why do gene therapies still occupy only a minimal market share
in their respective indications?
- What can be learned from the gene therapies that have already
reached the market?
A number of different viral and non-viral vector types are
currently in development for the delivery of gene therapies -
- What are the relative advantages and disadvantages of each
vector type and which hold the most promise?
- What proportion of the overall gene therapy R&D pipeline is
occupied by each vector type?
Check for Discount @
https://wiseguyreports.com/check_discount/gene-therapies-a-diverse-range-of-technologies-with-a-promising-long-term-outlook
. (Single User License - $2995)
The current pipeline for gene therapies is diverse in terms of
the approaches and vectors covered; 50% are gene silencing
therapies, while 31% involve the insertion of a functional gene
-
- In which therapy areas is there the highest level of R&D
activity for gene therapies?
- At which stage of development does the majority of pipeline
gene therapies reside?
- What is the proportion of the pipeline occupied by each
intervention and vector type overall?
A number of companies are currently actively developing pipeline
gene therapies, including private, public and institutional
enterprises -
- How do gene therapies fit into the overall portfolios of these
companies?
- What is the level of involvement in gene therapy research from
the top 20 Big Pharma companies?
Reasons to buy "Gene Therapies A Diverse Range of
Technologies with a Promising Long-Term Outlook" report
includes: Understand the current status of the field of
therapeutic gene therapies, and the relative clinical and
commercial success of currently marketed products, comprising
Glybera, Kynamro, Macugen, Vitravene, Gendicine, Oncorine, and
Neovasculgen.; Assess the pipeline for gene therapies split by
therapy area, vector type and intervention type, and stage of
development. Additionally, a granular assessment of the pipeline is
provided across the four major therapy areas for gene therapy:
oncology, infectious diseases, central nervous system disorders,
and genetic disorders.; Gain a picture of the current competitive
landscape, with a detailed breakdown of companies actively involved
in the gene therapy pipeline. Understand the level of involvement
on the part of big pharma companies, and the extent to which gene
therapies fit into the overall portfolios of companies in this
field. Additionally, a highly granular breakdown of companies
developing multiple gene therapies is provided.
Browse more reports on Pharmaceutical Industry at
https://wiseguyreports.com/categories/pharmaceutical .
Related reports on Gene Therapies Industry:
PharmaSphere: Emerging Biotechnologies - Gene Therapy Market
Analysis
This report is an essential source of information and analysis
on the gene therapy field. Using detailed company data, deal
analysis, corporate strategy, and market trends analysis,
GlobalData provides an in-depth analysis of the current and future
growth drivers of the gene therapy market. The report discusses the
key factors shaping and driving the gene therapy business, and
provides insights on the competitive landscape and emerging
strategies expected to significantly influence the market positions
of companies currently involved in the development and
commercialization of gene therapies. Companies mention in this
report include Advantagene, ALS Therapy Development Institute,
Amarna Therapeutics, American Gene Technologies International,
AnGes MG, Applied Genetic Technologies Corporation, Asklepios
BioPharmaceutical, Avalanche Biotechnologies, Bluebird bio,
Celladon, Dimension Therapeutics, GeneCure Biotechnologies,
Genethon, GenSight Biologics, Oxford BioMedica, ReGenX Biosciences,
Sangamo BioSciences, Spark Therapeutics, UniQure, Voyager
Therapeutics.
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd.
and offers premium progressive statistical surveying, market
research reports, analysis & forecast data for industries and
governments around the globe. We also provide COTS (Commercial off
the Shelf) business sector reports as custom exploration agreeing
your particular needs.
Media Contact: Norah
Trent, WiseGuy Reports, +1 646 845 9349,
sales@wiseguyreports.com
News distributed by PR Newswire iReach:
https://ireach.prnewswire.com
SOURCE WiseGuy Reports